Home/ Stocks/ CTNM

Contineum Therapeutics, Inc. Class A Common Stock

CTNM XNAS

$14.53 -0.10 (-0.68%) ▼ 15-min delayed

Open

$14.61

High

$14.89

Low

$14.31

Volume

133.4K

Market Cap

$543.22M

About Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 51 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-14,456,000	$-0.39
FY 2025	$0	$-59,978,000	$-2.17
Q3 2025	$0	$-12,792,000	$-0.45
Q2 2025	$0	$-16,040,000	$-0.62

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for CTNM yet. Check out our latest market news or earnings calendar.

Get CTNM Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Contineum Therapeutics, Inc. Class A Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.